CLEVELAND, Feb. 8 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), today announced that the Company is scheduled to present at the Roth Capital Partners 19th Annual OC Conference to be held February 19-22, in Dana Point, CA. Michael Fonstein, Ph.D., President and Chief Executive Officer at Cleveland BioLabs, will give a presentation on the company followed by a question and answer session on February 22, at 9:00 a.m. PST. The presentation will be broadcast live over the Internet. Interested parties may tune in to the live presentation by visiting the company's website at: http://www.cbiolabs.com/ or alternatively at http://www.wsw.com/webcast/roth9/cbli/. Cleveland BioLabs currently has two lead compounds in late stages of development. Curaxin CBLC102 is a small molecule designed to kill tumor cells by simultaneously targeting two key regulators of apoptosis. The Company has initiated a Phase II trial with CBLC102 in hormone refractory prostate cancer. The Company's other lead compound, Protectan CBLB502, is a modified protein of a microbe that protects cells from apoptosis. CBLB502 is the first compound of its kind to provide protection from both gastrointestinal and hematopoietic (bone marrow/blood production) radiation-induced damage. Other applications for this technology include protection from cancer treatment side effects. Cleveland BioLabs recently announced a new discovery regarding its Protectan 600 series of compounds being developed for radiation protection. A single administration of CBLB612, the lead compound in the Protectans 600 series, in healthy mice resulted in a three-fold increase in the number of progenitor (originator) stem cells in mouse bone marrow within 24 hours after administration. Moreover, the number of these stem cells in peripheral blood was increased 10-fold within four days of administration. Dr. Fonstein will be available for investor meetings at the conference. About Cleveland BioLabs, Inc. Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute. To learn more about Cleveland BioLabs Inc., please visit the company's website at http://www.cbiolabs.com/. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in our Registration Statement on Form SB-2/A filed with the Securities and Exchange Commission on September 8, 2006. Contact: The Global Consulting Group Rachel Levine T: (646) 284-9439 E: DATASOURCE: Cleveland BioLabs, Inc. CONTACT: Rachel Levine of The Global Consulting Group, +1-646-284-9439, or Web site: http://www.cbiolabs.com/ http://www.wsw.com/webcast/roth9/cbli

Copyright